RBC Capital lowered the firm’s price target on Repligen (RGEN) to $189 from $202 but keeps an Outperform rating on the shares after its Q1 results. The company’s post-pandemic rebound remains on track, with minimal exposure to macro and U.S. policy headwinds faced by the rest of the Life Science Tools sector, the analyst tells investors in a research note. RBC adds however that its price target cut is due to market multiple compression.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RGEN:
- Repligen’s Fair Valuation and Cautious Growth Outlook Lead to Hold Rating
- Repligen Reports Strong Q1 2025 Financial Results
- Repligen’s Earnings Call Highlights Robust Growth and Strategic Moves
- Repligen price target lowered to $190 from $200 at JPMorgan
- Repligen upgraded to Outperform from Peer Perform at Wolfe Research
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue